NVN Liquidation

NVN Liquidation, Inc. (formerly Novan, Inc.) is a clinical-stage biotechnology company focused on leveraging its proprietary NO-based technology platform, NITRICIL™, to generate macromolecular new chemical entities (NCEs) for the treatment of diseases in dermatology, men's and women's health, infectious diseases with significant unmet needs, and gastroenterology. The company’s lead product candidate is SB206, a topical antiviral gel being developed for the treatment of molluscum contagiosum. The company believes that SB206, as a topical, at-home, caregiver-applied therapy, offers rapid treatment benefits and, if approved, would address a critical patient care need in the treatment of molluscum contagiosum.